Profound Medical Corp. (PROF)

Market Cap	188.42M
Revenue (ttm)	8.98M
Net Income (ttm)	-31.39M
Shares Out	24.66M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,481
Open	7.77
Previous Close	7.83
Day's Range	7.40 - 7.77
52-Week Range	7.11 - 11.42
Beta	0.83
Analysts	Strong Buy
Price Target	11.40 (+48.24%)
Earnings Date	Nov 7, 2024

About PROF

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Arun Menawat
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: PROF
• Website: https://www.profoundmedical.com

Financial Performance

In 2023, Profound Medical's revenue was $7.20 million, an increase of 7.75% compared to the previous year's $6.68 million. Losses were -$28.57 million, -0.35% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for PROF stock is "Strong Buy." The 12-month stock price forecast is $11.4, which is an increase of 48.24% from the latest price.

Price Target

$11.4

(48.24% upside)

Analyst Consensus: Strong Buy